Congress: Movement Disorder Society (MDS) International Congress 2026
Dates: October 4-8, 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Theme: Understanding Aging in Movement Disorders
Overview
flowchart TD
MDS_2026___PD_Genetic_and_Mole["MDS 2026 PD Genetic and Molecular Mechanisms"]
MDS_2026___PD_Genetic_and_Mole["Congress"]
MDS_2026___PD_Genetic_and_Mole -->|"related to"| MDS_2026___PD_Genetic_and_Mole
style MDS_2026___PD_Genetic_and_Mole fill:#81c784,stroke:#333,color:#000
MDS_2026___PD_Genetic_and_Mole["Movement"]
MDS_2026___PD_Genetic_and_Mole -->|"related to"| MDS_2026___PD_Genetic_and_Mole
style MDS_2026___PD_Genetic_and_Mole fill:#81c784,stroke:#333,color:#000
MDS_2026___PD_Genetic_and_Mole["Disorder"]
MDS_2026___PD_Genetic_and_Mole -->|"related to"| MDS_2026___PD_Genetic_and_Mole
style MDS_2026___PD_Genetic_and_Mole fill:#81c784,stroke:#333,color:#000
style MDS_2026___PD_Genetic_and_Mole fill:#4fc3f7,stroke:#333,color:#000
The MDS 2026 congress will feature industry-sponsored sessions, satellite symposia, and poster presentations showcasing pharmaceutical company pipelines for movement disorders. This page tracks the expected industry presentations and drug development programs["@mds"].
Parkinson's Disease Pipeline
Disease-Modifying Therapies ... Congress: Movement Disorder Society (MDS) International Congress 2026
Dates: October 4-8, 2026
Location: Seoul, Korea — COEX Convention and Exhibition Center
Theme: Understanding Aging in Movement Disorders
Overview
Mermaid diagram (expand to render)
The MDS 2026 congress will feature industry-sponsored sessions, satellite symposia, and poster presentations showcasing pharmaceutical company pipelines for movement disorders. This page tracks the expected industry presentations and drug development programs["@mds"].
Parkinson's Disease Pipeline
Disease-Modifying Therapies | Drug/Program | Company | Mechanism | Stage |
Symptomatic Therapies
Extended-Release Formulations: Novel delivery systemsContinuous Infusion Therapies: Levodopa-carbidopa intestinal gelAdenosine A2A Antagonists: Istradefylline approved, follow-ons in developmentAdvanced Therapies
Gene Therapy: AAV-based approaches (AAV2-GAD, AADC)Cell Therapy: Stem cell-derived dopamine [neurons](/entities/neurons)Deep Brain Stimulation: Directional leads, closed-loop systemsHuntington's Disease Pipeline
Gene-Targeting Therapies | Drug/Program | Company | Mechanism | Stage |
Disease-Modifying Approaches
Molecular Chaperones: Protein aggregation inhibitorsNeuroprotective Agents: Mitochondrial protectorsAnti-inflammatory Therapies: Microglial modulationRare Movement Disorders Pipeline
Ataxias
CoQ10 and Analogues: For Friedreich's ataxia and mitochondrial disordersAntisense Oligonucleotides: SCA1, SCA3 programsGene Therapy: AAV-based frataxin deliveryDystonia
DBS Devices: New-generation directional leadsBotulinum Toxin: New formulationsSmall Molecules: Novel muscle relaxantsIndustry Sessions Expected
Satellite Symposia Major pharmaceutical companies typically host satellite symposia covering:
Clinical trial results
Pipeline updates
Expert panels on treatment strategies
Poster Sessions Industry and academic researchers present:
Phase 1/2 trial results
Preclinical data
Real-world evidence studies
Exhibition Hall
Company booths with product information
Clinical trial recruitment
Medical affairs discussions
Key Companies Expected
AbbVie — [Parkinson's disease](/diseases/parkinsons-disease), dystoniaBiogen — LRRK2 inhibitors, [Alzheimer's](/diseases/alzheimers-disease)Boehringer Ingelheim — Parkinson's diseaseBristol Myers Squibb — Parkinson's diseaseDenali Therapeutics — LRRK2, GBA, TNFEli Lilly/Prevail — Gene therapy Ipsen — Botulinum toxinsMerck — Parkinson's diseaseNovartis — Parkinson's disease, SMANovo Nordisk — GLP-1, neurodegenerationRoche — Huntington's diseaseTakeda — Rare movement disordersUCB — Epilepsy, movement disordersClinical Trial Design Topics
Biomarker-Driven Trials: Using biomarkers for patient selectionAdaptive Designs: Platform trials, master protocolsDisease Progression Models: Long-term outcome predictionDigital Endpoints: Wearable devices, digital biomarkersRelated Pages
[MDS 2026](/events/mds-2026) — Main congress page](/events)
[MDS 2026 — Parkinson's Disease Sessions](/events/mds-2026-parkinsons-sessions)](/events)
[MDS 2026 — Huntington's Disease Sessions](/events/mds-2026-huntingtons-sessions)](/events)
[MDS 2026 — Rare Movement Disorders](/events/mds-2026-rare-movement-disorders)](/events)
[Clinical Trials in Parkinson's](/gaps/prodromal-prevention-trial-design-parkinsons)
See Also
References
Unknown, MDS Congress Website (n.d.)
Unknown, J Parkinsons Dis. 2024 - Clinical Trial Pipeline (2024) Show full description